XTRA:SAP
XTRA:SAPSoftware

SAP (XTRA:SAP) Profit Margin Surges, Challenging Expectations for Sustained Turnaround

SAP (XTRA:SAP) delivered a sharp profit turnaround, with net profit margins rising to 19.4% from 8.3% previously and annual earnings growth increasing 158%, in stark contrast to its former five-year average annual decline of 4.1%. Estimates now call for annual earnings growth of 14.4% and revenue growth of 11.1%. Both figures are expected to outpace the wider German market's anticipated 6% annual revenue increase, while net earnings growth is expected to lag just behind the market at 16.6%...
XTRA:SY1
XTRA:SY1Chemicals

Assessing Symrise’s Valuation After 7% Jump and Expansion News in 2025

If you’ve been watching Symrise stock lately, you’re not alone in wondering whether now is the right time to make a move. After all, the company’s share price has jumped 3.0% in the last week and 7.2% over the past month. Yet, when you zoom out, the bigger picture is more complex. Year to date, Symrise is down about 20.8%, and over the last five years, it has slipped by more than 20%. These numbers might make you pause and ask what’s really driving the stock’s story right now. Some of this...
XTRA:TMV
XTRA:TMVSoftware

TeamViewer (XTRA:TMV) Margin Beat Reinforces Bullish Narratives Despite Share Price Discount

TeamViewer (XTRA:TMV) posted robust earnings, with net profit margins rising to 17.8% from 16.3% a year ago. Over the last five years, annual earnings have grown by 11.1%, while the most recent twelve months saw a 19.6% jump in earnings. With earnings forecast to grow by 14.1% per year and revenue expected to increase at 7.7% annually, outpacing the broader German market, investors have plenty of growth drivers to watch. At the same time, share price and financial stability risks remain part...
XTRA:GXI
XTRA:GXILife Sciences

Should FDA Approval of Lasix ONYU Prompt a Closer Look at Gerresheimer’s (XTRA:GXI) Growth Path?

On October 13, 2025, SQ Innovation received FDA approval for Lasix ONYU, a combination product featuring Gerresheimer’s proprietary on-body infusor for at-home subcutaneous drug delivery in select congestive heart failure patients. This milestone showcases Gerresheimer’s technological capabilities in advanced drug delivery devices and highlights its growing position as a full-service partner to pharmaceutical companies embracing home-based care. Next, we’ll explore how the FDA-backed rollout...
XTRA:CEC
XTRA:CECSpecialty Retail

Ceconomy’s (XTRA:CEC) Index Exit: Could Shifting Investor Demand Change Its Strategic Path?

Ceconomy AG was recently removed from the Germany Small DAX (Total Return) Index, changing its status among tracked German equities. This exclusion may affect its visibility and demand from funds that track the index, influencing the company’s relationship with institutional investors. We’ll explore how Ceconomy's index removal may impact its investment case, especially regarding its profile among index-oriented investors. We've found 18 US stocks that are forecast to pay a dividend yield of...
XTRA:CON
XTRA:CONAuto Components

Continental (XTRA:CON): Is the Stock Still Undervalued After Strong Q3 Results and Guidance Reaffirmation?

Continental (XTRA:CON) released preliminary third-quarter numbers that landed above market expectations, with sales and adjusted EBIT margin both coming in ahead of estimates. The company’s Tires and ContiTech segments played a key role. See our latest analysis for Continental. Continental’s upbeat preliminary earnings have sparked a strong recovery in its share price, with an 11% rally in just one day and a 7% gain over the past week. While the stock had been under pressure through late...
XTRA:GXI
XTRA:GXILife Sciences

A Look at Gerresheimer (XTRA:GXI) Valuation After FDA Approval of New On-Body Drug Delivery Device

Gerresheimer (XTRA:GXI) shares drew renewed attention after news that the US FDA approved the Lasix ONYU combination product, which features the company’s proprietary on-body drug delivery device. This regulatory win could prove commercially meaningful with 2025 launches approaching. See our latest analysis for Gerresheimer. Despite the lift from FDA approval of its new drug delivery device, Gerresheimer's share price has continued to face heavy pressure, with a 30-day share price return of...